Other studies have also shown that EZH2 inhibitors act against the cancer stem cell population in pancreatic cancer and glioblastoma.39, 40, 41 These findings indicate that EZH2 inhibitors may be promising agents for cancer stem cell-targeting therapy. The gene discussed is EZH2; the disease is familial pancreatic carcinoma.